肝细胞癌
免疫组织化学
CD8型
免疫系统
肿瘤微环境
医学
癌
渗透(HVAC)
内科学
病理
肿瘤科
免疫学
物理
热力学
作者
Toshihiko Yusa,Yo‐ichi Yamashita,Hirohisa Okabe,Yosuke Nakao,Rumi Itoyama,Yuki Kitano,Takayoshi Kaida,Tatsunori Miyata,Kosuke Mima,Katsunori Imai,Hiromitsu Hayashi,Hideo Baba
出处
期刊:Cancer Science
[Wiley]
日期:2022-05-25
卷期号:113 (12): 4048-4058
被引量:10
摘要
Inflammatory and immune cells in the tumor microenvironment are reported to be associated with tumor progression in several cancers. In total, 225 patients who underwent initial and curative hepatectomy for hepatocellular carcinoma (HCC) from 2004 to 2013 were enrolled in this study. Tumor-associated neutrophils (TANs), M2 macrophages (TAMs; tumor-associated macrophages), CD8+ T cells, and regulatory T cells (Tregs) were evaluated by immunohistochemistry (IHC), and their relationships with patient clinicopathological characteristics and prognosis were evaluated. IHC was performed focusing on TANs first. We could not find a relationship between intratumoral and peritumoral TANs and clinicopathological features except for the fibrous capsule and infiltration of tumors into capsule. Next, TAMs, CD8+ cells and Tregs were evaluated by IHC. At the peritumoral area, TANs and TAMs (r = 0.36, p = 0.001) or Tregs (r = 0.16, p = 0.008) showed a positive correlation, whereas TANs and CD8+ cells showed a negative correlation (r = -0.16, p = 0.02). As for survival outcomes, at the peritumoral area, high TANs (p = 0.0398), low CD8+ cells (p = 0.0275), and high TAMs (p = 0.001) were significantly associated with worse overall survival (OS). In addition, high TANs (p = 0.010), and high TAMs (p = 0.00125) were significantly associated with worse disease-free survival (DFS). Finally, we established a risk signature model by combining the expression patterns of these cells. The high-risk signature group had significantly worse OS (p = 0.0277) and DFS (p = 0.0219) compared with those in the low-risk signature group. Our risk signature based on immune cells at the peritumoral area of the HCC can predict patient prognosis of HCC after curative hepatectomy.
科研通智能强力驱动
Strongly Powered by AbleSci AI